Rindopepimut: anti-EGFRvIII peptide vaccine, oncolytic.

  title={Rindopepimut: anti-EGFRvIII peptide vaccine, oncolytic.},
  author={Patrick C Gedeon and Bryan D. Choi and John H. Sampson and Darell D Bigner},
  journal={Drugs of the future},
  volume={38 3},
Glioblastoma, the most common primary malignant brain tumor, is among the most difficult cancers to treat. Despite the aggressive standard of care, including surgical removal followed by radiotherapy with concomitant and adjuvant chemotherapy, the often sudden onset, diffuse infiltrating nature and highly malignant features of the lesion result in a median overall survival of < 15 months. Currently employed standard- of-care therapy for glioblastoma is nonspecific, leading to premature… CONTINUE READING